JIR
RNAC icon

James Investment Research’s Cartesian Therapeutics RNAC Stock Holding History

James Investment Research’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,192
Closed -$102K – 315
2023
Q3 		$102K Hold
3,192
– – 0.01% 270
2023
Q2 		$107K Buy
3,192
+2,008
+170% +$71.9K 0.01% 267
2023
Q1 		$49K Buy
+1,184
New +$55.7K 0.01% 366

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

James Investment Research's RNAC Position: Q4 2023 in Review

James Investment Research sold out of Cartesian Therapeutics (RNAC) in Q4 2023, closing a stake of 3,192 shares — an estimated $102K sold.

James Investment Research first reported a position in RNAC in Q1 2023 and held it in 3 quarters. The position peaked at $107K in Q2 2023. 80 funds tracked by Wall St. Rank hold RNAC as of Q4 2023.

  • James Investment Research reported no remaining Cartesian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • James Investment Research sold 3,192 Cartesian Therapeutics shares in Q4 2023, an estimated $102K.
  • James Investment Research first reported a position in Cartesian Therapeutics in Q1 2023 and held it in 3 quarters.
  • James Investment Research's Cartesian Therapeutics position peaked at $107K in Q2 2023.
  • 80 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2023.

Based on James Investment Research's 13F filing for Q4 2023, filed 6 Feb 2024.